Song Chou

Role: CRISPR Therapeutics
Location: Cambridge, MA, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

Experience

CRISPR Therapeutics
Present

Education

Shanghai Institute of Biochemistry, Chinese Academy of Sciences
Master of Science (M.S.), Molecular Biology
Nanjing University
Bachelor of Science (B.S.), Biochemistry
UC Irvine
Doctor of Philosophy (Ph.D.), Molecular Biology
1997 — 2004

Skills

Rare Diseases
Sickle Cell Disease
Project Management
Epigenetics
Stem Cells
Assay Development
Molecular Biology
Qpcr
Molecular Cloning
Antibody Drug Conjugates
Genetics
Cell Signaling
Drug Discovery
Hematopoiesis
Western Blotting
Tissue Targeting
Drug Delivery
Mouse Bone Marrow Transplant
Cell Biology
Cell Culture
Flow Cytometry

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@crisprtx.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

CRISPR Therapeutics

Biotechnology Research · 343 employees · Founded 2013 · Boston, Massachusetts, United States

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

crisprtx.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Education

Shanghai Institute of Biochemistry, Chinese Academy of Sciences

Nanjing University

UC Irvine

Skills

Find verified contacts for anyone on LinkedIn